Familial hypercholesterolaemia: PCSK9 inhibitors are coming

Lancet. 2015 Jan 24;385(9965):307-10. doi: 10.1016/S0140-6736(14)61702-5. Epub 2014 Oct 1.

Authors

Raul D Santos¹, Gerald F Watts²

Affiliations

¹ Lipid Clinic, Heart Institute (InCor), University of Sao Paulo Medical School Hospital and Preventive Medicine Centre and Cardiology Program, Hospital Israelita Albert Einstein, Sao Paulo, SP 05403, Brazil. Electronic address: raul.santos@incor.usp.br.
² Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia.

PMID: 25282517
DOI: 10.1016/S0140-6736(14)61702-5

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents / administration & dosage*
Female
Humans
Hyperlipoproteinemia Type II / drug therapy*
Male
Proprotein Convertase 9
Proprotein Convertases / antagonists & inhibitors*
Serine Endopeptidases

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
PCSK9 protein, human
Proprotein Convertase 9
Proprotein Convertases
Serine Endopeptidases
evolocumab